Seelos Therapeutics has signed a strategic device partnership agreement with Aptar Pharma for the use of Aptar's Bidose Liquid System (BDS) for Seelos' SLS-002 intranasal ketamine, Seelos said. SLS-002 is in Phase 2 development for the treatment of suicidal ideation in patients with major depressive disorder. The company noted that the agreement also includes the … [Read more...] about Seelos says it has signed an agreement to use Aptar Pharma’s BDS device for its intranasal ketamine
Business
FDA approves Tyvaso inhalation solution for the treatment of PH-ILD
According to United Therapeutics, the FDA has approved Tyvaso treprostinil inhalation solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). Tyvaso has been approved for the treatment of pulmonary arterial hypertension since July 2009. United Therapeutics submitted the sNDA for the PH-ILD indication in August 2020, … [Read more...] about FDA approves Tyvaso inhalation solution for the treatment of PH-ILD
Iconovo to develop inhaled COVID-19 vaccine delivered by the ICOone device for ISR
According to Iconovo, Swedish immunotherapy developer Immune System Regulation (ISR) will pay up to 18.1 million Swedish kronor plus potential royalties for development of a dry powder COVID-19 vaccine delivered via Iconovo’s ICOone single dose DPI. The deal also includes an option for ISR to use the ICOone device for delivery of vaccines for other respiratory … [Read more...] about Iconovo to develop inhaled COVID-19 vaccine delivered by the ICOone device for ISR
Valeo Pharma gets Canadian rights to Enerzair Breezhaler and Atectura Breezhaler
Valeo Pharma has acquired the rights to commercialize Novartis' Enerzair Breezhaler indacaterol / glycopyrronium / mometasone furoate and Atectura Breezhaler indacaterol / mometasone furoate) DPIs in Canada, the company said. Terms of the deal were not announced. Valeo CEO Steve Saviuk said, "We are extremely pleased to be partnering with Novartis to launch these … [Read more...] about Valeo Pharma gets Canadian rights to Enerzair Breezhaler and Atectura Breezhaler
Leyden Labs raises €40 Million for development of intranasal vaccines
Dutch startup Leyden Laboratories, which has formed to develop intranasal vaccines, has closed a €40 Million Series A financing led by GV (formerly known as Google Ventures), the company said. Leyden Labs was founded by former Mckinsey Partner Koenraad Wiedhaup, Janssen Senior Advisor Jaap Goudsmit, and former Crucell CEO Ronald Brus, with Wiedhaup as CEO, Goudsmit as … [Read more...] about Leyden Labs raises €40 Million for development of intranasal vaccines
LloydsPharmacy to launch Starpharma’s Viraleze nasal spray in the UK
Starpharma has announced the signing of a UK sales and distribution agreement for its Viraleze astodrimer sodium antiviral nasal spray with LloydsPharmacy and its parent company McKesson, with LloydsPharmacy set to launch the nasal spray on its web site within a week and in its stores sometime in April 2021. Viraleze was approved for sale in the UK and in Europe in … [Read more...] about LloydsPharmacy to launch Starpharma’s Viraleze nasal spray in the UK
Sino Biopharm acquires SMI developer Softhale
Sino Biopharmaceutical Limited will pay $110 million up front in addition to a share of profits for Belgian soft mist inhaler developer Softhale. According to New Rhein, the fund's investments to acquire a 60% stake in Softhale were made in 2019 and 2020. Softhale is led by Jan-Torsten Tews, who previously headed respiratory drug groups at Sandoz, Teva, and GSK. … [Read more...] about Sino Biopharm acquires SMI developer Softhale
Bausch Health gets Canadian rights to Glenmark’s Ryaltris nasal spray
Bausch Health has acquired the rights to commercialize Glenmark’s Ryaltris olopatadine / mometasone furoate nasal spray in Canada, Glenmark has announced. According to Glenmark, which is responsible for regulatory approval under the agreement with Bausch, Health Canada is currently reviewing the company's marketing application for Ryaltris for the treatment of … [Read more...] about Bausch Health gets Canadian rights to Glenmark’s Ryaltris nasal spray
Sandoz acquires rights to Proventil HFA MDI and authorized generic
Sandoz said that the company has acquired distribution rights to the brand and to an authorized generic of Proventil HFA albuterol MDI from Kindeva Drug Delivery and has already launched the generic MDI in the US. Proventil HFA was first marketed in the US by Schering and then by Merck. In April 2019, Par Pharmaceuticals announced that it had launched an … [Read more...] about Sandoz acquires rights to Proventil HFA MDI and authorized generic
Chiesi launches Bronchitol mannitol DPI in the US
Chiesi USA has announced the US launch of Bronchitol dry powder mannitol for the treatment of cystic fibrosis in adult patients. The FDA approved the Bronchitol DPI in November 2020. The company also announced the publication of data from its Phase 3 trial of Bronchitol in the Journal of Cystic Fibrosis. Chiesi also distributes the DPI, which was developed by … [Read more...] about Chiesi launches Bronchitol mannitol DPI in the US